The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases
- PMID:19509315
- DOI: 10.1124/jpet.109.153973
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases
Abstract
Vedolizumab is a humanized monoclonal antibody that targets the alpha(4)beta(7) integrin exclusively, and modulates inflammation in the gastrointestinal tract without inducing the systemic immunosuppression that characterizes anti-alpha(4) chain monoclonal antibodies, such as natalizumab. This unique pharmacologic profile is largely attributable to four determinants. The first determinant is the restriction of the expression of the alpha(4)beta(7) integrin to subsets of leukocytes. Vedolizumab does not bind to the majority of memory CD4(+) T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (approximately 25%) of human peripheral blood memory CD4(+) T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4(+) T and B lymphocytes with subnanomolar potency (EC(50) = 0.3-0.4 nM). The second determinant is binding specificity; vedolizumab binds exclusively to the alpha(4)beta(7) integrin, and not to the alpha(4)beta(1) and alpha(E)beta(7) integrins. The third determinant is selective antagonism; vedolizumab selectively inhibits adhesion of alpha(4)beta(7)-expressing cells to mucosal addressin cell adhesion molecule 1 (median inhibition concentration [IC(50)] = 0.02-0.06 microg/ml) and fibronectin (IC(50) = 0.02 microg/ml), but not vascular cell adhesion molecule 1. The fourth determinant is the gastrointestinal-specific tropism of the alpha(4)beta(7) integrin function. These pharmacologic properties of vedolizumab, in conjunction with the gastrointestinal tropism of alpha(4)beta(7) integrin function, may ultimately confer an improved risk-to-benefit profile for patients with inflammatory bowel diseases.
Similar articles
- A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation.Rott LS, Briskin MJ, Andrew DP, Berg EL, Butcher EC.Rott LS, et al.J Immunol. 1996 May 15;156(10):3727-36.J Immunol. 1996.PMID:8621908
- Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ.Fedyk ER, et al.Inflamm Bowel Dis. 2012 Nov;18(11):2107-19. doi: 10.1002/ibd.22940. Epub 2012 Mar 14.Inflamm Bowel Dis. 2012.PMID:22419649
- Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.Binder MT, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, Atreya R, Neufert C, Atreya I, Neurath MF, Zundler S.Binder MT, et al.Inflamm Bowel Dis. 2018 May 18;24(6):1237-1250. doi: 10.1093/ibd/izy077.Inflamm Bowel Dis. 2018.PMID:29788362
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.Wyant T, Fedyk E, Abhyankar B.Wyant T, et al.J Crohns Colitis. 2016 Dec;10(12):1437-1444. doi: 10.1093/ecco-jcc/jjw092. Epub 2016 Jun 1.J Crohns Colitis. 2016.PMID:27252400Review.
- Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.Lamb CA, O'Byrne S, Keir ME, Butcher EC.Lamb CA, et al.J Crohns Colitis. 2018 Aug 22;12(suppl_2):S653-S668. doi: 10.1093/ecco-jcc/jjy060.J Crohns Colitis. 2018.PMID:29767705Review.
Cited by
- Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.Pan WJ, Hsu H, Rees WA, Lear SP, Lee F, Foltz IN, Rathanaswami P, Manchulenko K, Chan BM, Zhang M, Xia XZ, Patel SK, Prince PJ, Doherty DR, Sheckler CM, Reynhardt KO, Krill CD, Harder BJ, Wisler JA, Brandvig JL, Lynch JL, Anderson AA, Wienkers LC, Borie DC.Pan WJ, et al.Br J Pharmacol. 2013 May;169(1):51-68. doi: 10.1111/bph.12134.Br J Pharmacol. 2013.PMID:23425116Free PMC article.
- Phosphorylation of RIAM Activates Its Adaptor Function in Mediating Integrin Signaling.Su B, Wu J.Su B, et al.J Cell Signal. 2021;2(2):103-110. doi: 10.33696/signaling.2.041.J Cell Signal. 2021.PMID:35128538Free PMC article.
- Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease.Mehandru S, Colombel JF, Juarez J, Bugni J, Lindsay JO.Mehandru S, et al.Mucosal Immunol. 2023 Dec;16(6):859-870. doi: 10.1016/j.mucimm.2023.08.001. Epub 2023 Sep 3.Mucosal Immunol. 2023.PMID:37574127Free PMC article.Review.
- How natalizumab binds and antagonizes α4 integrins.Yu Y, Schürpf T, Springer TA.Yu Y, et al.J Biol Chem. 2013 Nov 8;288(45):32314-32325. doi: 10.1074/jbc.M113.501668. Epub 2013 Sep 18.J Biol Chem. 2013.PMID:24047894Free PMC article.
- Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.Christensen B, et al.Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.Inflamm Bowel Dis. 2018.PMID:29562271Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials